These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 2148433)

  • 1. Comparison of the immunogenicity of hepatitis B vaccine administered intradermally and intramuscularly.
    King JW; Taylor EM; Crow SD; White MC; Todd JR; Poe MB; Conrad SA; Gelder FB
    Rev Infect Dis; 1990; 12(6):1035-43. PubMed ID: 2148433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody response after intradermal administration of recombinant hepatitis B vaccine in children.
    Wiström J; Gustafsson A
    Scand J Infect Dis; 1990; 22(5):621-2. PubMed ID: 2148015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intramuscular versus low-dose intradermal hepatitis B vaccine. Assessment by humoral and cellular immune response to hepatitis B surface antigen.
    Frazer IH; Jones B; Dimitrakakis M; Mackay IR
    Med J Aust; 1987 Mar; 146(5):242-5. PubMed ID: 2950303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative trial of low-dose, intradermal, recombinant- and plasma-derived hepatitis B vaccines.
    Bryan JP; Sjogren M; Iqbal M; Khattak AR; Nabi S; Ahmed A; Cox B; Morton A; Shuck J; Macarthy P
    J Infect Dis; 1990 Oct; 162(4):789-93. PubMed ID: 2144866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in haemodialysis patients.
    Fujiyama S; Yoshida K; Sato T; Shimada H; Deguchi T
    Hepatogastroenterology; 1990 Dec; 37 Suppl 2():140-4. PubMed ID: 2150664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens.
    Soulié JC; Devillier P; Santarelli J; Goudeau A; Vermeulen P; Guellier M; Saliou P; Hillion AM; Tron F; Huchet J
    Vaccine; 1991 Aug; 9(8):545-8. PubMed ID: 1837646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose (2 micrograms) hepatitis B vaccination in medical students: comparable immunogenicity for intramuscular and intradermal routes.
    Heijtink RA; Knol RM; Schalm SW
    J Med Virol; 1989 Feb; 27(2):151-4. PubMed ID: 2522147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine.
    Waite NM; Thomson LG; Goldstein MB
    J Am Soc Nephrol; 1995 May; 5(11):1930-4. PubMed ID: 7620090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intradermal hepatitis B immunization with yeast-derived vaccine: serological response by sex and age.
    Morris CA; Oliver PR; Reynolds F; Selkon JB
    Epidemiol Infect; 1989 Oct; 103(2):387-94. PubMed ID: 2530104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suboptimal response following intradermal hepatitis B vaccine in infants.
    Coberly JS; Townsend T; Repke J; Fields H; Margolis H; Halsey NA
    Vaccine; 1994 Aug; 12(11):984-7. PubMed ID: 7975851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of response to intramuscular versus low dose intradermal hepatitis B booster immunization.
    McKinney WP; Russler SK; Horowitz MM; Battiola RJ; Lee MB
    Infect Control Hosp Epidemiol; 1991 Apr; 12(4):226-30. PubMed ID: 1829469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intradermal hepatitis B vaccination in an abbreviated schedule.
    Halsey NA; Reppert EJ; Margolis HS; Francis DP; Fields HA
    Vaccine; 1986 Dec; 4(4):228-32. PubMed ID: 3541426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review of the efficacy and safety of intradermal versus intramuscular hepatitis B vaccination in end-stage renal disease population unresponsive to primary vaccination series.
    Yousaf F; Gandham S; Galler M; Spinowitz B; Charytan C
    Ren Fail; 2015 Aug; 37(7):1080-8. PubMed ID: 26258528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of low-dose intradermal recombinant DNA hepatitis B vaccine.
    Parish DC; Muecke HW; Joiner TA; Pope WT; Hadler SC
    South Med J; 1991 Apr; 84(4):426-30. PubMed ID: 1826567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose hepatitis B vaccination in children.
    Milne A; Allwood GK; Pearce NE; Lucas CR; Krugman S
    N Z Med J; 1986 Feb; 99(795):47-9. PubMed ID: 2935755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose intradermal versus intramuscular administration of recombinant hepatitis B vaccine: a comparison of immunogenicity in infants and preschool children.
    Egemen A; Aksit S; Kurugöl Z; Erensoy S; Bilgiç A; Akilli M
    Vaccine; 1998 Oct; 16(16):1511-5. PubMed ID: 9711797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers.
    Henderson EA; Louie TJ; Ramotar K; Ledgerwood D; Hope KM; Kennedy A
    Infect Control Hosp Epidemiol; 2000 Apr; 21(4):264-9. PubMed ID: 10782589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus vaccination for older adults.
    Bennett RG; Powers DC; Remsburg RE; Scheve A; Clements ML
    J Am Geriatr Soc; 1996 Jun; 44(6):699-703. PubMed ID: 8642163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine.
    Horowitz MM; Ershler WB; McKinney WP; Battiola RJ
    Ann Intern Med; 1988 Feb; 108(2):185-9. PubMed ID: 2963570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody responses to recombinant, yeast-derived hepatitis B vaccine in teenage New Zealand children.
    Milne A; Moyes CD; Allwood GK; Pearce NE; Krugman S
    N Z Med J; 1988 Feb; 101(840):67-9. PubMed ID: 2967940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.